Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Irritable Bowel Syndrome
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Irritable Bowel Syndrome
    Amitriptyline as Effective as Placebo for Pain Relief of IBS in Children - (DGNews)
    Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial - (BMJ)
    Patients With IBS Report Similar Satisfaction for Drug Treatments, Alternative Therapies: Presented at DDW - (DGDispatch)
    ACG Publishes Evidence-Based Systematic Review on the Management of IBS - (DGNews)
    Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis - (BMJ)

    News archive

     Recent webcasts/CME - Irritable Bowel Syndrome
    • Latest Data on Individualizing Induction and Maintenance Therapy in Patients With IBD: Selecting Appropriate Treatment Regimens for Optimal Patient Outcomes
    • Considerations for Optimal Selection of Therapy for Patients With Active IBD: Inducing Remission Quickly and Effectively
    • Exploring Maintenance Therapy Strategies in IBD: How Will New Data on Biologics, Combinations, and Postoperative Therapy Impact Practice?
    • Evidence-Based Management of Irritable Bowel Syndrome: A Guide for Primary Care
    • Irritable Bowel Syndrome with Constipation (IBS-C): Improving Patient Care Assessment and Management

      Webcasts/CME archive

       Recent cases - Irritable Bowel Syndrome
        Small Bowel Gastrointestinal Stromal Tumors Can Physiologically Alter Gut Motility Before Causing Mechanical Obstruction
        Irritable Bowel Syndrome
        Dietary Therapy of Irritable Bowel Syndrome

        Cases archive
          




        my personal edition > irritable bowel syndrome > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Placebo-Controlled Trial Shows Which IBS Patients Respond to Probiotic Treatment: Presented at ACG

        By Paula Moyer

        HONOLULU, HI -- November 3, 2005 -- Patients with irritable bowel syndrome (IBS) who have symptoms of hard stool or urgency are the most likely to respond to the probiotic agent Bifidobacterium infantis 35624 (Bifantis), according to research presented here at the 70th annual meeting of the American College of Gastroenterology (ACG).

        Probiotics are bacterial strains. Patients with IBS often buy probiotics as supplements over-the-counter, said principal investigator Eamonn M. M. Quigley, MD, Professor of Medicine and Human Physiology, Alimentary Pharmabiotic Center of National University of Ireland, Cork, Ireland.

        "There is an increasing demand for well-designed trials regarding probiotic agents," he said during his presentation on November 1st. "Whether you look at animal models or tissue culture models, there is an emerging amount of data regarding probiotics, so there is now a basis in science."

        In the current research, Dr. Quigley and his co-investigators conducted a double-blind, placebo-controlled trial of B. infantis 35624 in IBS patients. They then analyzed the patients' baseline characteristics to see whether any specific symptoms predicted whether patients would respond to treatment.

        Of the 173 patients, 87 were in the treatment group and 86 were in the placebo group. At the end of the 4-week treatment phase, 55 patients in the treatment group (63.2%) and 40 patients in the placebo group responded to treatment (46.5%).

        Among responders, those with hard stool were nearly three times as likely to respond to treatment, with an odds ratio of 2.84. Those with urgency were 1.45 times as likely to respond as other patients.

        Dr. Quigley said that patients who had symptoms of straining were less likely to respond, with an odds ratio of 0.33.

        When the investigators adjusted for baseline predictors, those in the treatment group were 2.15 times as likely to respond as those in the placebo group.

        The study was funded by Procter & Gamble, which manufactures Bifantis. Dr. Quigley is a consultant and shareholder in the company.


        [Presentation title: Who is the Responder to Probiotic Therapy in IBS? Data from a Controlled Clinical Trial with Bifidobacterium Infantis 35624. Abstract 827]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send